Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.…
DYAI: First Product Sales Are Modest
Dyadic International (NASDAQ: DYAI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 5 employees.
The shares were at 0.2870 USD on 20 November 2026, down 69.1% over 52 weeks. Its 52-week range is 0.2850 USD to 1.600 USD, and it trades at the bottom of that range.
Its market capitalisation is 11.51M USD.
Dyadic International reports an operating margin of -194.5% and revenue down 0.6% year over year.
Its debt exceeds its cash by 1.93M USD, a debt-to-equity ratio of 4.11. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 24 March 2027.